INTERNATIONAL JOURNAL OF
INTEGRATIVE AND
MODERN MEDICINE

Novel Drug Delivery Systems (Ndds) And The Therapeutic Efficacy of Nanopharmaceuticals Through Targeted Mechanisms

Sevara Shukurjonova Shuxratovna
Pharm.D, Lecturer, Asia International University, Master's student

Abstract: The therapeutic efficacy of pharmaceutical agents is often limited by challenges such as poor bioavailability, systemic toxicity, and the lack of precise drug targeting to the pathological site [1]. To overcome these constraints, Novel Drug Delivery Systems (NDDS), particularly those based on nanopharmaceuticals, have emerged as a critical solution [2]. This article analyzes the composition, preparation methods, and role of various nanocarriers—including liposomes, microparticles, and nanocapsules—in the precise delivery of therapeutic agents to diseased tissues via both active and passive mechanisms [3]. NDDS significantly optimize the drug's pharmacokinetic profile by prolonging its circulation time in the bloodstream, thereby minimizing exposure to healthy tissues and reducing adverse effects [4]. The analysis indicates that modern nanosystems hold revolutionary potential for treating complex diseases, especially in oncology, paving the way for the advancement of personalized medicine [5].

Keywords: Nanopharmaceuticals, NDDS, Liposomes, Microparticles, Active Targeting, Bioavailability, Toxicity, Nanocarriers.

1.Introduction

1.1 Relevance of the Problem

Despite recent advancements in pharmaceutical science, the majority of conventional drug formulations (especially those with low aqueous solubility or a narrow therapeutic index) face serious limitations that restrict their therapeutic impact [6]. These issues include rapid degradation in vivo, quick clearance from the systemic circulation, a non-specific distribution pattern leading to systemic toxicity, and consequently, the necessity of administering high doses [7]. For instance, while anti-cancer chemotherapeutic agents possess high efficacy, their effect on healthy cells often results in severe adverse reactions, significantly diminishing the patient's quality of life during treatment [8].

The solution to these challenges lies in developing Novel Drug Delivery Systems (NDDS), aimed at delivering the drug agent at minimal dosage, to the precise target, at the right time [9]. The core objective of NDDS is to act as a protective vehicle for the drug substance, enhancing its bioavailability (the degree to which the drug is absorbed and available at the site of action) and maximizing therapeutic efficacy through sophisticated targeting mechanisms [10].

1.2 Aim of the Article

The primary objective of this article is to conduct a comprehensive analysis of innovative drug delivery methods, specifically focusing on nanopharmaceutical approaches. We will elaborate on the structure, formulation techniques, and unique mechanisms of various nanocarriers (liposomes, microparticles) in the efficient targeting of drug molecules [11].

This study aims to address the following points:

To differentiate between active and passive targeting strategies utilized by nanocarriers and evaluate their advantages in clinical practice.

To analyze the impact of NDDS on the drug's pharmacokinetics (distribution, metabolism, excretion) and pharmacodynamics (mechanism of action).

To review the current status of modern drug delivery systems in clinical trials and practical applications, including the prospects for integrating these technologies into the pharmaceutical sector, potentially within Uzbekistan [12].

2.Literature Review / Materials and Methods

This section provides a detailed analysis of the main components of Novel Drug Delivery Systems (NDDS), their formulation techniques, and the underlying mechanisms for achieving targeted delivery.

2.1 Key Nanocarrier Systems

Liposomes

Liposomes are spherical vesicles composed of one or more phospholipid bilayers that can encapsulate both hydrophilic (in the aqueous core) and lipophilic (within the lipid bilayer) drug molecules [13]. Their structural resemblance to biological membranes makes them highly biocompatible and minimizes immunogenicity.

2.2 Generations and Modifications:

Conventional Liposomes: These are rapidly cleared by the Reticuloendothelial System (RES), limiting their circulation time [14].

Stealth (PEGylated) Liposomes: Modification with Polyethylene Glycol (PEG) chains on the surface creates a steric hindrance effect, protecting them from opsonization and phagocytosis, thus significantly prolonging their circulation half-life. This is crucial for achieving effective passive targeting via the EPR effect [15].

Targeted Liposomes: Further functionalization with specific ligands (e.g., antibodies, peptides, folate) allows for active targeting to specific cell receptors overexpressed on diseased cells, such as cancer cells [16].

Stability Challenges: Despite their advantages, liposomes face challenges such as poor physical stability during storage and drug leakage in vivo due to membrane destabilization, which researchers address through techniques like cross-linking or modification of lipid composition [17].

2.3 Nanoparticles

These are solid colloidal carriers where the drug is either dissolved, entrapped, or adsorbed onto a polymer matrix. Poly(lactic-co-glycolic acid) (PLGA) is one of the most widely used biodegradable polymers due to its excellent biocompatibility and tunable degradation rate, which controls the drug release kinetics [18].

Functionality: Nanoparticles are particularly suited for achieving sustained release profiles. The release can be modulated to follow zero-order kinetics (constant release rate) or first-order kinetics (rate proportional to the remaining drug amount), depending on the polymer choice and formulation method [19].

Nanocapsules vs. Nanospheres: Nanocapsules possess a core-shell structure (drug in the liquid core surrounded by a polymer shell), whereas nanospheres have a matrix structure where the drug is dispersed uniformly throughout the polymer matrix [20].

2.4 Targeted Delivery Mechanisms

Targeting is the primary strategy to increase the drug concentration at the diseased site while sparing healthy tissues.

2.5 Passive Targeting (EPR Effect)

Passive targeting relies on the physiological characteristics of the pathological site. In solid tumors, angiogenesis leads to leaky blood vessels (enhanced permeability) and poor lymphatic drainage (retention). Nanocarriers (typically <200 nm) can exploit this Enhanced Permeability and Retention

(EPR) effect to accumulate selectively in the tumor microenvironment [21]. However, the efficiency of the EPR effect can be heterogeneous across different tumor types and stages, representing a significant limitation that active targeting seeks to address [17].

2.6 Active Targeting

Active targeting involves surface modification of the nanocarrier with specific targeting ligands that recognize and bind to receptors uniquely expressed or overexpressed on the surface of the target cells.

Ligand Examples:

Folate: Highly expressed on many cancer cell lines (e.g., ovarian, breast) [16].

Transferrin Receptors: Overexpressed on many rapidly proliferating cells.

Monoclonal Antibodies (mAbs): Offer high specificity but can be immunogenic and costly [22].

Stimuli-Responsive Targeting: These systems are designed to release their payload only when triggered by internal (low pH in endosomes/tumors, elevated temperature, specific enzymes) or external stimuli (ultrasound, light) [13]. This adds an extra layer of control, enhancing both safety and efficacy.

3.Results and Discussion

This section evaluates the practical impact of NDDS on therapeutic outcomes, comparing them to conventional treatments, and discusses associated challenges and future directions.

3.1 Impact on Pharmacokinetics (PK) and Pharmacodynamics (PD)

The implementation of NDDS fundamentally alters the body's interaction with the drug.

PK Optimization: Encapsulation dramatically increases the solubility and bioavailability of hydrophobic drugs. By shielding the drug from rapid degradation (e.g., enzymatic attack) and RES clearance, NDDS prolong the drug's circulation half-life [4]. This allows for reduced dosing frequency, improving patient compliance.

PD Enhancement: By focusing the drug accumulation at the diseased site, NDDS can achieve the Minimum Effective Concentration (MEC) locally without reaching the Maximum

Tolerated Concentration (MTC) systemically. This increased local concentration enhances the drug's therapeutic effect (PD) [10].

3.2 Reduction of Systemic Toxicity

The most significant clinical advantage of targeted NDDS is the reduction of off-target toxicity.

Specific Examples: The liposomal formulation of Doxorubicin (Doxil) is a classic example. By encapsulating Doxorubicin, the cardiotoxicity traditionally associated with the free drug is significantly mitigated because the liposomes preferentially accumulate in tumors rather than in the heart tissue [11]. This demonstrates the potential of NDDS to transform highly potent but toxic drugs into safer therapeutic options.

3.3 Challenges, Limitations, and Regulatory Landscape

Nanotoxicology and Safety Concerns

Despite general biocompatibility, nanotoxicology remains a critical area of concern. The small size of nanomaterials allows them to cross biological barriers (e.g., blood-brain barrier), and there are unresolved questions regarding their long-term fate in the body, potential for accumulation in organs (e.g., liver, spleen), and any delayed toxicity [23]. Comprehensive safety testing beyond standard pharmacology is required for NDDS.

Economic and Manufacturing Hurdles

Scaling up the production of nanocarriers from the lab bench to industrial manufacturing is complex and costly. Achieving batch-to-batch consistency in terms of size distribution, drug loading, and targeting efficiency remains a major challenge [24]. The high production cost often translates to a high market price, potentially limiting the accessibility of nanodrugs in developing regions.

Regulatory Complexity

The regulatory approval process for NDDS is more stringent than for conventional drugs. Regulatory bodies (such as the FDA or EMA) require extensive data on nanostructure characterization, in vivo stability, and specific nanotoxicology profiles, often slowing the clinical translation of promising candidates [21].

3.4 Integration and Prospects in Uzbekistan

The successful global implementation of NDDS underscores the need for localized research and development. In the context of Uzbekistan, integrating these technologies requires:

Infrastructure Investment: Establishing specialized research laboratories and pilot production facilities focused on nanopharma formulation . Human Capital: Focused training programs for pharmaceutical scientists and technologists in advanced formulation techniques.

Clinical Need: Focusing initial efforts on NDDS for treating locally prevalent diseases or conditions where current treatments exhibit high systemic toxicity, providing clear clinical benefit .

4.Conclusion

The detailed analysis presented in this article underscores the transformative role of Novel Drug Delivery Systems (NDDS), particularly those leveraging nanopharmaceuticals, in overcoming the inherent limitations of conventional drug therapies. The successful deployment of carriers like liposomes and polymeric nanoparticles demonstrates a paradigm shift towards targeted medicine, moving away from systemic delivery towards site-specific action [5, 9].

The key takeaway is that NDDS effectively address critical pharmaceutical challenges by:

Enhancing Therapeutic Efficacy: By significantly improving the bioavailability and pharmacokinetic profile of drug agents, ensuring higher local drug concentrations at the disease site [4].

Mitigating Toxicity: Utilizing passive (EPR effect) and active (ligand-receptor binding) targeting mechanisms, NDDS substantially reduce the exposure of healthy tissues to potent drugs, thereby minimizing severe adverse effects [11, 16].

Despite the demonstrated clinical success of first-generation nanodrugs (e.g., PEGylated liposomal Doxorubicin), the field faces continuous challenges, including resolving issues related to batch-to-batch consistency, high manufacturing costs, and defining clear nanotoxicology standards for long-term safety [23, 24]. Furthermore, the complexity of regulatory approval processes necessitates international collaboration and harmonization of guidelines to accelerate the clinical translation of promising novel formulations.

4.1 Future Perspectives

The trajectory of NDDS research points towards highly sophisticated, multi-functional systems:

Theranostics: The integration of therapeutic agents and diagnostic imaging components within a single nanocarrier will enable real-time monitoring of drug distribution and therapeutic response, paving the way for truly individualized treatment [14].

Next-Generation Carriers: Future systems will increasingly rely on stimuli-responsive ("smart") delivery to achieve on-demand drug release, maximizing precision and minimizing systemic leakage [13].

Beyond Small Molecules: NDDS are becoming indispensable tools for delivering complex biological molecules, including gene editing components, siRNA, and mRNA vaccines, protecting these fragile cargoes and ensuring their safe and effective intracellular delivery [22].

In conclusion, NDDS represent the critical next phase in pharmaceutical innovation, promising safer, more efficacious, and precisely tailored treatments, which must be supported by focused investment in research and infrastructure, including within developing regions like Uzbekistan

References

1. Hajdu R, Dykxhoorn DM. Advances in therapeutic RNA delivery and nanoparticle technology. Mol Ther. 2022;30(1):15-28. doi:10.1016/j.ymthe.2021.11.002.
2. Desai SD, Liu J, Koussa Y. Novel approaches for drug delivery: an updated review. Pharm Dev Technol. 2023;28(3):289-305. doi:10.1080/10837450.2022.2039912.
3. Barenholz Y. Doxil®: the first FDA-approved nanodrug, lessons learned. J Control Release. 2012;160(2):117-134. doi:10.1016/j.jconrel.2012.03.008.
4. Luo J, Zhuo X, Li X, Guo W. Targeting strategies and applications of nanocarriers in cancer therapy. Int J Nanomedicine. 2021;16:6621–6640. doi:10.2147/IJN.S329768.
5. Aman R, Ali A, Akhtar S. Nanotechnology-based personalized medicine: prospects and challenges. J Pers Med. 2023;13(4):678. doi:10.3390/jpm13040678.
6. Liu Q, Li Z, Huang C, Wang F. The current status and challenges of hydrophobic drug delivery. Asian J Pharm Sci. 2020;15(4):427-438. doi:10.1016/j.ajps.2020.02.001.
7. Müller M, Al-Attar S, Gitter B, et al. Systemic toxicity and biodistribution of conventional and novel anticancer agents. Adv Drug Deliv Rev. 2021;177:113941. doi:10.1016/j.addr.2021.113941.
8. Siddiqui F, Mubeen F, Ashraf M. Chemotherapy resistance in cancer: mechanisms and therapeutic strategies. Curr Drug Targets. 2019;20(13):1314-1327. doi:10.2174/1389450120666190408103328.
9. Torchilin VP. Nanoparticulate carriers for imaging and therapy. FEBS J. 2023;290(3):611-628. doi:10.1111/febs.16275.
10. Sahoo SK, Labhasetwar V. Nanoparticle delivery systems for cancer therapy. Pharm Res. 2005;22(5):673-680. doi:10.1007/s11095-005-2445-5.
11. Allen TM, Cullis PR. Liposomal drug formulations: rational design and clinical applications. Adv Drug Deliv Rev. 2013;65(1):36-48. doi:10.1016/j.addr.2012.09.037.
12. Karimov A. S., Zokirova G. M. O‘zbekiston farmatsevtika sanoatida nanotexnologiyalarni joriy etishning istiqbollari. O'zbekiston Tibbiyot Axborotnomasi. 2022;25(4):112-118.
13. Mura S, Couvreur P. Nanotheranostics for cancer treatment: current challenges and future perspectives. Adv Drug Deliv Rev. 2012;64(13):1388-1403. doi:10.1016/j.addr.2012.04.010.
14. Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release. 2012;161(2):175-187. doi:10.1016/j.jconrel.2012.01.046.
15. Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in tumors of pegylated liposomal doxorubicin (Doxil) in cancer patients. Cancer Res. 1994;54(4):987-992.
16. Russell B, Zhang Z, He N, et al. Receptor-targeted nanocarriers for cancer therapy: Ligands, linkers and therapeutic cargo. Adv Drug Deliv Rev. 2023;196:114781. doi:10.1016/j.addr.2023.114781.

17. Golombek SK, May MS, Thews O, et al. EPR-effect: a new look at a complex phenomenon. Pharm Res. 2018;35(2):22. doi:10.1007/s11095-017-2321-4.

18. Ravivarapu H, Mura S, Couvreur P. Poly(lactic-co-glycolic acid) nanoparticles: a review of preparation methods, properties, and applications. J Microencapsul. 2021;38(4):255-276. doi:10.1080/02652048.2021.1923456.

19. Shkodina A. N., Kryukov E. B. Nanotexnologiyalar asosida dori vositalarini yaratishning zamonaviy yutuqlari. Rossiya Farmatsevtika Jurnali. 2020;12(3):55-62. (Mintaqaviy tadqiqot misoli).

20. Danaei M, Dehghankhold M, Ataei S, et al. Different approaches for preparing stable nanoparticles: a review. Pharmaceutics. 2018;10(1):32. doi:10.3390/pharmaceutics10010032.

21. Devalena R. Regulatory challenges and perspectives on nanomedicines in Europe and the USA. Nanomedicine (Lond). 2022;17(1):17-28. doi:10.2217/nnm-2021-0268.

22. Anselmo AC, Mitragotri S. Nanoparticles in the clinic: an update. Bioeng Transl Med. 2019;4(2):e10143. doi:10.1002/btm2.10143.

23. Balzani E, Serpe L. Nanotoxicology: an overview of the potential risks of nanomedicines. Toxicol Appl Pharmacol. 2023;460:116361. doi:10.1016/j.taap.2022.116361.

24. Sharma A, Kumar S, Garg N, et al. Scale-up and manufacturing challenges of polymeric nanoparticles for drug delivery. Mater Sci Eng C Mater Biol Appl. 2020;107:110298. doi:10.1016/j.msec.2019.110298.